Ipamorelin
Studied for: selective secretagogue
Ipamorelin is a selective growth-hormone secretagogue. Research examines it specifically for its selectivity, releasing growth hormone with minimal effect on cortisol or prolactin.
Last reviewed September 26, 2026
How it is thought to work
Research describes ipamorelin as a ghrelin receptor agonist studied for stimulating growth hormone release without the broader hormonal activity of earlier secretagogues.
- Receptor SelectivityStudied for acting at the ghrelin receptor with minimal associated cortisol or prolactin response.
- Pulsatile ReleaseExplored for producing a release pattern that resembles the body's own rhythm.
- Route studied
- Subcutaneous
- Receptor class
- GHS-R1a
- Research status
- Preclinical
The primary studies on Ipamorelin are animal studies of growth hormone release and bone growth, while more recent reviews discuss it among unapproved peptides, so controlled human evidence is limited.
Research
What the research covers
What research examines
- Selective growth hormone release
- Minimal cortisol and prolactin response
- Longitudinal bone growth in rats
- Body composition in reviews of GH secretagogues
- Musculoskeletal and sports medicine peptide research
Reported effects in studies
- Human safety data are limited
- Early research reported minimal effects on cortisol and prolactin
- Recent reviews assess it among unapproved peptide therapies
- Reviews discuss its use in sport and bodybuilding in a doping context
Studied range
What research protocols have used
Research protocols have used 200–500 mcg per administration, 5 days per week (evening, fasted), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- GLP-3RGLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three affects metabolic regulation differently to dual or single agonists.Read profile$119
- CJC-1295CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone analog with a short half-life, studied specifically for preserving the body's natural pulsatile release pattern.Read profile$119
- BPC-157BPC-157 is a synthetic sequence derived from a protein found in gastric juice. Research examines its role in gut barrier integrity, connective-tissue repair, and the signaling that coordinates healing.Read profile$49
- TesamorelinTesamorelin is a stabilized growth-hormone-releasing hormone analog. Research examines its role in endogenous GHRH signaling and its association with visceral adipose tissue.Read profile$99
Studies
Cited research
- Ipamorelin, the first selective growth hormone secretagogue.
European journal of endocrinology · 1998 · PMID 9849822
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999 · PMID 10373343
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
Translational andrology and urology · 2020 · Review · PMID 32257855
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.) · 2026 · Review · PMID 41966639
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
The Journal of sports medicine and physical fitness · 2026 · Review · PMID 41880199
FAQ
Questions about Ipamorelin
Ipamorelin is a synthetic growth hormone secretagogue. A 1998 paper described it as the first selective compound of this type. Research has focused on its selectivity. It stimulates growth hormone release with minimal reported effect on cortisol or prolactin, which set it apart from earlier secretagogues with broader hormonal activity. It is sold for laboratory research use only.
Research describes Ipamorelin as an agonist at the ghrelin receptor, GHS-R1a. Activating this receptor has been studied as a way to stimulate growth hormone release from the pituitary. Research has also explored whether Ipamorelin produces a pulsatile release pattern that resembles the body's own growth hormone rhythm. Its selectivity for growth hormone over cortisol and prolactin is the feature most often examined.
Early studies examined its selective growth hormone releasing activity. A 1999 study in rats reported that it induced longitudinal bone growth. More recent reviews discuss Ipamorelin alongside other growth hormone secretagogues in body composition research, orthopaedic and sports medicine, and healthy aging. These reviews generally frame it as an investigational compound, and controlled human outcome data remain limited.
Human safety data for Ipamorelin are limited. Early research emphasized its minimal effect on cortisol and prolactin compared with earlier secretagogues. Recent reviews assess the safety and efficacy of unapproved peptide therapies, including compounds of this class. Other reviews examine its use in recreational and professional sport and bodybuilding in a doping context. Adverse events are not comprehensively summarized in the cited studies.
Research protocols have used 200–500 mcg per administration, 5 days per week, in the evening in a fasted state. These protocols ran in 8-week blocks followed by 4 weeks off, and the route described is subcutaneous. These figures describe research protocols only. Each CoreX order ships with a protocol guide for laboratory reference.
Ask about Ipamorelin
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- CJC-1295 vs IpamorelinCJC-1295 and Ipamorelin are both peptides studied for their effects on growth hormone release, but they act through different receptor pathways. CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone (GHRH) analog with a short half-life. Research associates its brief action with preserving natural pulsatile release. Ipamorelin is a selective growth-hormone secretagogue that acts as a ghrelin receptor agonist, studied for releasing growth hormone with minimal cortisol or prolactin response. Published human data on CJC-1295 come mainly from small clinical studies of its long-acting DAC form. Ipamorelin's primary studies are animal work on growth hormone release and bone growth. Human safety data remain limited for both.
- Ipamorelin vs SermorelinIpamorelin and Sermorelin are both peptides studied for stimulating growth hormone release, but they act through different receptors. Ipamorelin is a selective growth hormone secretagogue described as a ghrelin receptor (GHS-R1a) agonist, examined for releasing growth hormone with minimal effect on cortisol or prolactin. Its primary studies are animal studies of growth hormone release and bone growth. Sermorelin is a synthetic GHRH analog that acts at the GHRH receptor (GHRH-R). Published reviews describe its clinical use in the diagnosis and treatment of idiopathic growth hormone deficiency in children, and it continues to be discussed in research on adult-onset growth hormone insufficiency. Human safety data are limited for Ipamorelin, and for Sermorelin outside pediatric research.